The authors

express their gratitude to Professor Egorov A. (HSC Development GmbH, Tulln, Austria) for his help in the production of recombinant influenza viruses expressing Brucella Omp16 or L7/L12 proteins. Also, thanks to Chervyakova O., PF-01367338 chemical structure senior researcher of the Research Institute for Biological Safety Problems, for the preparation and purification of Brucella L7/L12 and Omp16 proteins for staging ELISA and evaluation of a cellular immune response. The work was carried out under the project “Development of Products for Preventing Bovine Brucellosis” as part of the research program “Bovine Brucellosis: Monitoring the Epizoological Situation and Developing Means of Diagnosis and Prevention” for 2012–2014 funded by the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan. “
“Asthma is a common illness throughout the world which characterized with chronic airway inflammation, airway hyperresponsiveness (AHR) and airway remodeling. Despite advances in the understanding

of the mechanisms of allergic asthma, current therapies only alleviate/control the symptoms of asthma. There is a need to look for other treatment approaches. The recent world-wide changes in asthma prevalence imply significant environmental effects on asthma. Reduced exposure to bacteria or their products is associated with increased asthma, utilization of immunoregulatory treatments selleck products that based on bacterial components may have benefits for the suppression of asthma [1]. Studies demonstrated CpG-ODNs, BCG can inhibit allergic airway disease (AAD) in mouse models [2] and [3]. However, treatments with CpG-ODN may induce harmful side effects [2], while BCG has no efficacy on allergic asthma in human trials [4]. Pneumococci is a common respiratory pathogen, causing pneumonia, otitis media, meningitis and septicemia. Pneumococcal vaccination is recommended to prevent invasive pneumococcal infection in high-risk groups

including Sclareol asthmatics [5]. Epidemiological studies demonstrated that 7-valent pneumococcal conjugate vaccine (PCV7) immunization reduce the incidence of asthma and associated hospitalizations in both children and the elderly [6] and [7]. Thorburn et al. [8] stated PCV7 immunization in adulthood mice inhibit the hallmark features of AAD through promotion of Tregs and suppression of Th2 cells production. Recent studies indicated Th17 cells play vital role in asthma pathogenesis [9], [10] and [11]. Furthermore, PCV7 immunization is currently administered in infancy to prevent childhood pneumococci infections. Whether infant PCV7 immunization can alter young adulthood CD4+T cell subsets and inhibit AAD or not remains elusive. In this study we investigated the effects of infant PCV7 immunization on young adulthood AAD in mouse models.